Celldex Therapeutics CLDX Business Segments — Product Development Expenses

Similar metrics at other companies

IOVASingle Reportable — Research And Development Expense

$57.37M-13.1%

QURESingle Reportable — Laboratory And Development Expense

$14.76M-7.6%

CAPRSingle Reportable — Research And Development Expense

$27.38M+44.7%

MMSISingle Reportable — Research And Development Expense

$22.61M+0.6%

OCULSingle Reportable — Research And Development Expense Other Clinical And Preclinical Programs

$758K-14.7%

PTGXSingle Reportable — Employee Expense Benefit Related To Development

$5.95M+8.5%

Questions, answered.

What is Celldex Therapeutics's business segments — product development expenses?

Celldex Therapeutics (CLDX) reported business segments — product development expenses of $40.27M in Q4 2025.

How has Celldex Therapeutics's business segments — product development expenses changed year-over-year?

Celldex Therapeutics's business segments — product development expenses increased by 77.8% year-over-year, from $22.65M to $40.27M.

What is the long-term trend for Celldex Therapeutics's business segments — product development expenses?

Over 3 years (2022 to 2025), Celldex Therapeutics's business segments — product development expenses has grown at a 71.1% compound annual growth rate (CAGR), from $32.16M to $161.1M.

What does business segments — product development expenses mean?

This metric quantifies the direct financial resources dedicated to the clinical advancement and technical development of the company's pipeline assets. It highlights the company's focus on translating scientific research into viable therapeutic products. Investors use this to gauge the intensity and pace of the company's clinical trial activities.